Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
The deal gives Boehringer access to Gubra’s expertise in the design, synthesis and preclinical testing of therapeutic peptides.
The multiyear agreement positions Lilly to work with Topas on drugs that convey tolerance to antigens linked to inflammation or autoimmune diseases.
Arcus inked an $816 million deal for a PD-1 drug developed by Chinese firms WuXi Biologics and Gloria Pharmaceuticals.
The collaborators hope to learn about the role Sigma1 plays in disease and assess the activity of Context’s inhibitors of the protein.
DNA-encoded library technology expert HitGen just inked a multiyear, multitarget drug discovery deal with Aduro Biotech.
BeiGene is adding Medidata’s electronic patient-reported outcome solution to oncology clinical studies.
Sarepta offers Exondys 51 outside of the U.S. through a managed access program run by Clinigen, as an EMA decision is expected next year.
Telix has committed about $65 million in return for the exclusive right to use the antibodies to guide radioactive payloads to tumors.
Science Exchange will offer IndieBio-backed biotech startups access to its outsourced R&D platform.
It’s time again to call on you to nominate your Fierce 15 for 2017.